AsclepiX Therapeutics

AsclepiX Therapeutics is a biotechnology company focused on developing innovative peptide-based therapies for the treatment of retinal vascular diseases and cancer. The company's lead candidate, AXT107, is a synthetic peptide derived from collagen IV protein sequences. AXT107 works by inhibiting the pro-angiogenic VEGFR2 receptor and activating the vessel-stabilizing Tie2 receptor, addressing two key pathways in retinal vascular disease treatment. AsclepiX was founded by researchers from Johns Hopkins University School of Medicine and has since grown under the leadership of experienced biomedical and pharmaceutical executives. The company operates in the biopharmaceutical market, primarily serving patients with unmet medical needs in ocular diseases and oncology. AsclepiX's business model involves the rapid clinical development and commercialization of its novel therapeutics. Revenue is generated through the successful development and potential future sales of its drug candidates.

Keywords: peptide-based therapies, retinal diseases, cancer treatment, VEGFR2 inhibition, Tie2 activation, computational biology, Johns Hopkins, biopharmaceutical, clinical development, novel therapeutics.